Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Opthea Ltd ADR (OPT)

Opthea Ltd ADR (OPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Opthea Limited Appoints Kathy Connell as Non-Executive Director Ahead of Phase 3 Wet AMD Data Readout Quiver Quantitative, Inc. - Fri Nov 15, 4:16PM CST

Opthea appoints Kathy Connell as Non-Executive Director, enhancing business development expertise ahead of 2025 wet AMD data release.Quiver AI SummaryOpthea Limited has announced the appointment of Kathy...

OPT : 3.16 (+0.96%)
Dollars and Wallets - Pile of Money with Hands
2 Stocks Under $10 Wall Street Says Are 'Strong Buys' Barchart - Tue May 28, 8:59AM CDT

You can spend less and earn significant returns with these two cheap stocks.

TARA : 2.39 (+4.37%)
$SPX : 5,969.34 (+0.35%)
OPT : 3.16 (+0.96%)
Opthea To Present at Upcoming Investor Conferences Globe Newswire - Wed May 11, 2022

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea Presentation at The Retina World Congress 2022 Globe Newswire - Tue May 10, 2022

MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022 Globe Newswire - Thu May 5, 2022

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting Globe Newswire - Fri Apr 29, 2022

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea strengthens its Board of Directors Globe Newswire - Fri Apr 22, 2022

Elects Mr. Quinton Oswald and Dr. ...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference Globe Newswire - Thu Mar 10, 2022

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer Globe Newswire - Wed Mar 2, 2022

Key appointment as Opthea progresses the Phase 3 clinical development of OPT-302 in wet AMD MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) --...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 Globe Newswire - Mon Feb 14, 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical...

OPT.AX : 0.605 (-3.20%)
OPT : 3.16 (+0.96%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - Fri Nov 22, 6:00PM CST
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot